Gerresheimer updates its long-term guidance, shares tracked on Xetra

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 13:16.

Gerresheimer AG (DE000A0LD6E6) remains a core name in European healthcare packaging, with its shares trading on Xetra in Frankfurt. The company continues to highlight its long-term guidance framework and margin ambitions in its latest investor materials, underlining a strategy focused on higher-value pharma and biotech solutions.

Guidance framework and recent commentary

Gerresheimer outlines a mid-term ambition of organic revenue growth generally in the mid-single to high-single-digit percentage range, supported by robust demand for primary packaging for injectables and specialty pharma products. Management also targets a further improvement in adjusted EBITDA margins over time, driven by mix effects and efficiency programs in its plants.

In its capital markets and quarterly reporting, the company has reiterated that high-value solutions such as syringes, vials with special coatings, and drug delivery devices should grow faster than the group average, supporting the guidance trajectory. Market observers at brokers such as Deutsche Bank and Berenberg have referenced this framework in their valuation models, typically applying premiums versus more cyclical industrial peers.

Analyst views and sector comparison

Analyst consensus compiled by MarketScreener shows that a majority of covering analysts rate Gerresheimer shares as Buy or Outperform, with an average target price implying upside versus recent trading levels. This stance reflects expectations that the company will benefit from structural growth in injectable drugs and biologics packaging, similar to international peers like West Pharmaceutical Services.

Recent notes from banks such as Deutsche Bank and Berenberg emphasize the company's order visibility in medical devices and prefillable solutions, while also flagging execution risk around large investment projects. Sector comments in media like Handelsblatt also underline that pharma suppliers with strong niche positions can often defend margins better than broader industrial suppliers. Against this backdrop, Gerresheimer's reiterated guidance is seen as consistent with wider sector dynamics rather than an outlier.

What the company sells

Gerresheimer generates revenue mainly with primary packaging for injectable drugs, including glass vials, syringes and cartridges, as well as plastic containers and complex medical devices such as inhalers and auto-injectors for global pharma and biotech clients.

Where the stock trades today

Gerresheimer AG shares most recently traded on Xetra at around 100.00 euros per share, based on intraday data on 2026-06-26, 13:10.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.